scispace - formally typeset
E

Ella M. Meumann

Researcher at Charles Darwin University

Publications -  36
Citations -  414

Ella M. Meumann is an academic researcher from Charles Darwin University. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 7, co-authored 20 publications receiving 252 citations. Previous affiliations of Ella M. Meumann include Austin Hospital & Royal Hobart Hospital.

Papers
More filters
Journal ArticleDOI

Clinical Features and Epidemiology of Melioidosis Pneumonia: Results From a 21-Year Study and Review of the Literature

TL;DR: Melioidosis pneumonia is often a rapidly progressive illness with high mortality, particularly among those with multilobar disease, and risk factors have been identified.
Journal ArticleDOI

Clinical Evaluation of a Type III Secretion System Real-Time PCR Assay for Diagnosing Melioidosis

TL;DR: All six patients with melioidosis septic shock were blood PCR positive, suggesting potential for rapid diagnosis and commencement of appropriate therapy.
Journal ArticleDOI

Genomics-informed responses in the elimination of COVID-19 in Victoria, Australia: an observational, genomic epidemiological study.

TL;DR: The role of genomic epidemiology in the successful elimination of COVID-19 for a second time in Australia has been discussed in this paper, where the authors used phylogenetic analyses, genomic cluster discovery, and integrated results with epidemiological data collected via interview by the Victorian Government Department of Health.
Journal ArticleDOI

Genomic epidemiology of severe community-onset Acinetobacter baumannii infection.

TL;DR: The results suggest that international dissemination of A. baumannii is occurring in the community on a contemporary timescale and genes associated with biofilm formation and the type 6 secretion system may not be required for survival in community niches.
Journal ArticleDOI

The Darwin Prospective Melioidosis Study: a 30-year prospective, observational investigation

TL;DR: Melioidosis is an opportunistic infection with a diverse spectrum of clinical presentations and severity, and with early diagnosis, specific antimicrobial therapy, and state-of-the-art intensive care, mortality can be reduced to less than 10%.